Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 4/20 | 0.58 |
| ▸ | PLG | P00747 | 2/20 | 0.58 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.48 |
| ▸ | XIAP | P98170 | 4/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.47 |
| ▸ | F10 | P00742 | 1/20 | 0.45 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Efegatran SCHEMBL7273879 | 0.97 | F2 (0.56) | F2PLGPRSS1XIAPOPRM1 | |
| Efegatran SCHEMBL7264662 | 0.97 | F2 (0.56) | F2PLGPRSS1XIAPOPRM1 | |
| Efegatran SCHEMBL564291 | 0.97 | F2 (0.56) | F2PLGPRSS1XIAPOPRM1 | |
| Efegatran SCHEMBL7412481 | 0.97 | F2 (0.56) | F2PLGPRSS1XIAPOPRM1 | |
| Efegatran SCHEMBL1229047 | 0.96 | F2 (0.55) | F2PLGPRSS1XIAPOPRM1 | |
| Hydrochloric Acid SCHEMBL7296655 | 0.93 | F2 (0.59) | F2PLGPRSS1XIAPOPRM1 | |
| Hydrochloric Acid SCHEMBL7409436 | 0.92 | F2 (0.59) | F2PLGPRSS1XIAPOPRM1 | |
| SCHEMBL7448422 | 0.91 | F2 (0.58) | F2PLGPRSS1 | |
| SCHEMBL7446078 | 0.91 | F2 (0.56) | F2PLGPRSS1XIAPOPRM1 | |
| Acetic Acid SCHEMBL10728075 | 0.90 | F2 (0.56) | F2PLGOPRM1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1098 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12521258-B2 | Anticoagulant compounds and methods and devices for their use | ELIXIR MEDICAL CORPORATION (US) | 2026-01-13 | — | — | US | claimed |
| WO-2025262269-A1 | MONITORING OF REVERSAL AGENTS FOR ANTICOAGULANTS | ENZYRE B.V. (NL) | 2025-12-26 | — | — | WO | claimed |
| US-20240424175-A1 | ANTICOAGULANT COMPOUNDS COMPRISING CHELATING AGENTS AND CATIONIC ANTI-COAGULATION ENHANCERS AND METHODS AND DEVICES FOR THEIR USE | ELIXIR MEDICAL CORPORATION (US) | 2024-12-26 | — | — | US | claimed |
| WO-2024238703-A1 | ANTICOAGULANT COMPOSITIONS COMPRISING ANTI-PLATELET AND ANTI-INFLAMMATORY DRUGS AND METHODS AND DEVICES FOR THEIR USE | ELIXIR MEDICAL CORPORATION (US) | 2024-11-21 | — | — | WO | claimed |
| US-20240189495-A1 | METHODS OF PREPARING AN EXTRACORPOREAL CIRCUIT FOR ANTICOAGULATION | LOWELL THERAPEUTICS, LLC | 2024-06-13 | — | — | US | claimed |
| EP-4326363-A1 | METHODS OF PREPARING AN EXTRACORPOREAL CIRCUIT FOR ANTICOAGULATION | Lowell Therapeutics, LLC (US) | 2024-02-28 | — | — | EP | claimed |
| US-20230293540-A1 | ANTICOAGULANT COMPOUNDS, METHODS AND DEVICES FOR OPHTHALMIC USE | ELIXIR MEDICAL CORPORATION (US) | 2023-09-21 | — | — | US | claimed |
| US-20230190499-A1 | ANTICOAGULANT COMPOUNDS AND METHODS AND DEVICES FOR THEIR USE | ELIXIR MEDICAL CORPORATION (US) | 2023-06-22 | — | — | US | claimed |
| US-20230165874-A1 | ANTICOAGULANT COMPOUNDS AND METHODS AND DEVICES FOR THEIR PULMONARY USE | ELIXIR MEDICAL CORPORATION (US) | 2023-06-01 | — | — | US | claimed |
| WO-2023096800-A1 | ANTICOAGULANT COMPOUNDS COMPRISING CHELATING AGENTS AND CATIONIC ANTI-COAGULATION ENHANCERS AND METHODS AND DEVICES FOR THEIR USE | ELIXIR MEDICAL CORPORATION (US) | 2023-06-01 | — | — | WO | claimed |
| US-20020009753-A1 | Anticoagulant test | BEDNAR BOHUMIL (US) | 2002-01-24 | — | — | US | claimed |
| US-20010036913-A1 | Combination therapy for reducing the risks associated with cardiovascular disease | GOULD ROBERT J (US) | 2001-11-01 | — | — | US | claimed |
| US-6235706-B1 | Combination therapy for reducing the risks associated with cardiovascular disease | MERCK & CO., INC. | 2001-05-22 | — | — | US | claimed |
| US-6210904-B1 | DIAGNOSING FOR RISK OF THROMOCYTOPENIA BY DETECTING ABSENCE OF ASSOCIATION OF MONOCLONAL ANTIBODY WITH GLYCOPROTEIN IIB/IIA RECEPTOR:GLYCOPROTEIN IIB/IIA RECEPTOR ANTAGONIST COMPLEX | MERCK & CO., INC. | 2001-04-03 | — | — | US | claimed |
| US-6136804-A | ANTIISCHEMIC AGENTS, ANTITHROMBOTIC AGENTS, THROMBOTIC OCCLUSION AND ANTIPLATELET AGENT | MERCK & CO., INC. (US) | 2000-10-24 | — | — | US | claimed |
| US-6063584-A | Anticoagulant test | MERCK & CO., INC. (US) | 2000-05-16 | — | — | US | claimed |
| US-5978698-A | Angioplasty procedure using nonionic contrast media | MERCK & CO., INC. (US) | 1999-11-02 | — | — | US | claimed |
| WO-1997035579-A1 | A METHOD FOR INHIBITING CLOT FORMATION | MERCK & CO., INC. (US) | 1997-10-02 | — | — | WO | claimed |
| US-5455229-A | A tripeptide based on a alanine, proline and arginine derivative; protease inhibitors; myocardial infarctions | ELI LILLY AND COMPANY (US) | 1995-10-03 | — | — | US | claimed |
| EP-0606003-A1 | Method for minimizing and containing ischemic and reperfusion injury | ELI LILLY AND COMPANY (US) | 1994-07-13 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010036913-A1 | Combination therapy for reducing the risks associated with cardiovascular disease | HMGCR, PCSK9, APOB | F2 37/4885PLG 130/4885PRSS1 1039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.